1st Quarter - Report
ARENTFOX SCHIFF LLP for KEMPHARM, INC.
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
| SONJA NESBIT | — |
Pharmacy PHA
FDA regulation of opioid abuse deterrent formulations
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.